Triglycerides and cardiovascular disease

@article{Nordestgaard2014TriglyceridesAC,
  title={Triglycerides and cardiovascular disease},
  author={B{\o}rge Gr{\o}nne Nordestgaard and Anette Varbo},
  journal={The Lancet},
  year={2014},
  volume={384},
  pages={626-635}
}
After the introduction of statins, clinical emphasis first focussed on LDL cholesterol-lowering, then on the potential for raising HDL cholesterol, with less focus on lowering triglycerides. However, the understanding from genetic studies and negative results from randomised trials that low HDL cholesterol might not cause cardiovascular disease as originally thought has now generated renewed interest in raised concentrations of triglycerides. This renewed interest has also been driven by… Expand
Triglycerides and risk of atherosclerotic cardiovascular disease: An update.
TLDR
In patients with elevated triglycerides, several novel drugs are in development to reduce the residual risk on statin therapy linked to an excess of atherogenic triglyceride-rich lipoproteins. Expand
Triglycerides and residual risk.
TLDR
Evidence suggests higher triglycerides are a marker of CVRisk and may help identify patients who benefit from intensification of therapy and treatment with high-dose EPA may be of benefit in high-risk patients with hypertriglyceridemia to reduce CVRisks. Expand
Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk
TLDR
Among the new LDL-lowering therapies, PCSK9 inhibitors appear the most promising class and apolipoprotein(a), and triglyceride-rich lipoproteins, and the strategies to modulate HDL metabolism are described. Expand
Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management.
TLDR
Although omega-3 fatty acids are efficacious in lowering TG levels and may have pleiotropic effects such as reducing plaque instability and proinflammatory mediators of atherogenesis, clinical outcomes data are currently lacking. Expand
Triglycerides as Residual Risk for Atherosclerotic Cardiovascular Disease.
  • H. Ohmura
  • Medicine
  • Circulation journal : official journal of the Japanese Circulation Society
  • 2019
TLDR
Elevated serum TG levels are significantly associated with an increased risk of first major cardiovascular events (MACE) in patients with CAD treated with optimal medical therapy, indicating a possible pathogenetic role of these lipids in atherosclerosis rather than merely serving as biomarkers of disease risk. Expand
Hypertriglyceridaemia and risk of coronary artery disease
TLDR
Findings from several large studies indicate that elevated levels of triglycerides or, more specifically, triglyceride-rich lipoproteins and their remnants, are independently associated with increased risk of CVD. Expand
Remnant lipoproteins.
TLDR
Remnant cholesterol is a risk factor for cardiovascular disease, and can be lowered by different types of drugs; however, large scale studies of cardiovascular disease risk reduction through remnant lipoprotein lowering are under way. Expand
Remnant Cholesterol and Triglyceride-Rich Lipoproteins in Atherosclerosis Progression and Cardiovascular Disease.
TLDR
The main finding was that achieved concentrations of non-HDL cholesterol and achieve concentrations of triglycerides were closely associated with coronary atheroma progression and regression, irrespective of achieved concentrationsof low-density lipoprotein (LDL) cholesterol, C-reactive protein concentration, and diabetes mellitus status. Expand
Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia.
TLDR
Drugs that substantially, but not exclusively, lower TG and TG-rich lipoprotein cholesterol may have cardiovascular benefits in individuals with elevated TG, particularly if accompanied by low HDL-C. Expand
Triglycerides: A reappraisal.
TLDR
This review highlights some of the evidence that led to this stage and discusses the current data on pharmacologic intervention of triglyceride levels and the effect on clinical outcomes, to give the reader insight on what the most recent lipid guidelines state about clinical triglyceride management. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 100 REFERENCES
Triglycerides and Heart Disease: Still a Hypothesis?
TLDR
The purpose of this article is to review the basic and clinical science relating plasma triglycerides and cardiovascular disease and to suggest new and creative approaches to understanding the relationship of triglyceride and heart disease. Expand
Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.
TLDR
Clinicians are updated on the increasingly crucial role of triglycerides in the evaluation and management of CVD risk and highlight approaches aimed at minimizing the adverse public health–related consequences associated with hypertriglyceridemic states. Expand
Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.
TLDR
Bezafibrate was safe and effective in elevating HDL-C levels and lowering triglycerides and an overall trend in a reduction of the incidence of primary end points was observed. Expand
Effects of dalcetrapib in patients with a recent acute coronary syndrome.
TLDR
In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events. Expand
Remnant cholesterol as a causal risk factor for ischemic heart disease.
TLDR
A nonfasting remnant cholesterol increase of 1 mmol/l (39 mg/dl) is associated with a 2.8-fold causal risk for ischemic heart disease, independent of reduced HDL cholesterol, which implies that elevated cholesterol content of triglyceride-rich lipoprotein particles causes ischeMIC heart disease. Expand
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
TLDR
Among patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of less than 70 mg per deciliter, there was no incremental clinical benefit from the addition of niacin to statin therapy during a 36-month follow-up period, despite significant improvements in HDL cholesterol and triglyceride levels. Expand
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
TLDR
Recommendations will facilitate reduction in the substantial cardiovascular risk that persists in patients with cardiometabolic abnormalities at LDL-C goal, and that therapeutic targeting of elevated triglycerides, a marker of TRL and their remnants, and/or low HDL-C may provide further benefit. Expand
Nonfasting hyperlipidemia and cardiovascular disease.
TLDR
The results highlight the need for randomized double-blind trials of new and established drugs to reduce nonfasting triglycerides and remnant lipoprotein cholesterol, with the ultimate aim of reducing risk of cardiovascular disease and early death. Expand
Common variants associated with plasma triglycerides and risk for coronary artery disease
TLDR
It is suggested that triglyceride-rich lipoproteins causally influence risk for CAD, and the strength of a polymorphism's effect on triglyceride levels is correlated with the magnitude of its effect on CAD risk. Expand
Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment.
TLDR
Genetic and in-vitro and animal studies indicate that elevated LDL cholesterol levels cause atherosclerosis without a major inflammatory component, whereas an inflammatory component of Atherosclerosis is driven by elevated remnant cholesterol levels. Expand
...
1
2
3
4
5
...